This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignees: Consejo Superior De Investigaciones Cientificas, Fundacion Imabis. Instituto Mediterraneo Para El Avance De La Biotecnologia Y La Investigacion Sanitaria. Active years: 2012.
Company Filing History:
1 out of 477 
1 out of 1 Years Active: 2012
Title: Javier Pavon Moron: Innovator in Acyclic Sulfamide Derivatives
Introduction
Javier Pavon Moron is a notable inventor based in Málaga, Spain. He has made significant contributions to the field of medicinal chemistry, particularly through his innovative work on acyclic sulfamide derivatives. His research focuses on developing compounds that can aid in various health-related applications.
Latest Patents
Javier holds 1 patent for his invention titled "Acyclic sulfamide derivatives." This invention is related to compounds that are useful for the manufacture of a medicament aimed at inducing satiety and controlling ingestion. Additionally, these derivatives play a role in modulating corporal fat and regulating lipid metabolism. They are also beneficial for the treatment or prevention of diabetes and cardiovascular diseases, and have potential cosmetic applications.
Career Highlights
Throughout his career, Javier has worked with several esteemed organizations. He has been associated with Fundación IMABIS, Instituto Mediterráneo para el Avance de la Biotecnología y la Investigación Sanitaria, and Consejo Superior de Investigaciones Científicas. His work in these institutions has contributed to advancements in biotechnology and health research.
Collaborations
Javier has collaborated with notable colleagues, including Fernando Antonio Rodriguez De Fonseca and Manuel Macias Gonzalez. These partnerships have enhanced his research and development efforts in the field of medicinal chemistry.
Conclusion
Javier Pavon Moron is a distinguished inventor whose work on acyclic sulfamide derivatives has the potential to impact health and wellness significantly. His contributions to medicinal chemistry and collaborations with leading institutions highlight his commitment to innovation in this vital field.